# Menopausal hormone therapy and risk of neuropsychiatric disease: a drug target Mendelian randomisation study

## TL;DR

This study investigates how menopausal hormone therapy affects the risk of neurological and psychiatric diseases using genetic data.

## Contribution

The study uses Mendelian randomisation to explore the effects of oestrogen receptors on neuropsychiatric outcomes.

## Key findings

- Genetically proxied ERβ perturbation significantly increases the risk of depression.
- No evidence was found for effects on Alzheimer’s disease or brain structure.
- Results suggest psychiatric considerations for hormone therapy targeting oestrogen receptors.

## Abstract

Evidence on whether menopausal hormone therapy (MHT) affects neurological or psychiatric disease is conflicting. As MHT acts by binding to oestrogen receptors (ERα and ERβ), we used drug-target Mendelian randomisation (MR) to test whether perturbing these targets alters the risk of Alzheimer’s disease (AD), brain structure, depression, or anxiety. Genetic variants in the genes encoding these oestrogen receptors (ESR1 and ESR2) that were associated with positive controls were leveraged as instrumental variables. In two-sample MR analyses using large genome-wide association studies, genetically proxied ERα and ERβ perturbation showed no evidence of effect on AD or on cortical grey matter, hippocampal volume, or white matter hyperintensities. Genetically proxied ERβ perturbation significantly increased risk for depression (β = −0.66, 95% CI [−0.99, −0.32], p = 0.002), but not anxiety. Our study highlights psychiatric considerations when targeting oestrogen receptors with MHT, but provides no evidence for either harmful or protective effects on AD risk.